ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2026
scRNA-Seq reveals anti-lymphoma immune responses in mogamulizumab-associated skin eruptions.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mapping malignant T-cell states and immune circuits in Sézary syndrome by single-cell analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- scRNA-Seq reveals anti-lymphoma immune responses in mogamulizumab-associated skin eruptions.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundMogamulizumab is an anti-CCR4 therapeutic antibody approved for relapsed or refractory mycosis fungoides, Sézary syndrome and adult T-cell leukaemia/lymphoma. During treatment, a subset of patients develops a mogamulizumab-associated drug rash (MAR) that is associated with a better overall survival, but underlying mechanisms remain unclear. In addition, misinterpretation of MAR as cutaneous T-cell lymphoma (CTCL) progression can lead to unnecessary drug discontinuation.
objectivesTo conduct a comprehensive molecular characterization of MAR.
methodsWe performed single-cell RNA sequencing of skin biopsies from 4 patients with MAR, compared to untreated erythrodermic CTCL (CTCL, n = 6) and healthy control (HC, n = 4) skin.
resultsCCR4 was primarily expressed in proliferating and non-proliferating malignant T-cell clones and FOXP3+ regulatory T cells in untreated CTCL, which were significantly decreased in MAR. The few residual malignant clones in MAR showed retained CCR4 expression, but decreases in the central memory markers SELL and CCR7, with upregulation of the MMP2 inhibitor TIMP2 and the tumour suppressor gene RUNX3, consistent with a more silenced immune phenotype. In parallel, polyclonal T cells in MAR lesions exhibited decreases in the exhaustion markers TIGIT and TOX, paralleled by upregulation of markers associated with cytotoxicity (GZMA) and anti-cancer properties (ZNF683). This increase in tumour suppressor and cytotoxicity genes potentially reflects an anti-lymphoma immune response within the MAR skin microenvironment.
conclusionsOur study provides novel insights into the molecular properties of residual malignant clones within MAR that appear silenced, surrounded by a putatively anti-tumor immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.